Tibet Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TBET research report →
Company
Tibet Pharmaceuticals, Inc. , a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. The company, through its operational entity, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), develops products in China for promoting health in human respiratory, digestive, urinary, and reproductive systems.
- CEO
- Hong Yu
- IPO
- 2023
- Employees
- 190
- HQ
- Wanchai, HK
Price Chart
Valuation
- Market Cap
- $1.49K
- P/E
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 49.98%
- Op Margin
- 41.14%
- Net Margin
- 40.61%
- ROE
- 77.26%
- ROIC
- 0.00%
Growth & Income
- Revenue
- $32.36M · 40.67%
- Net Income
- $13.14M · 42.15%
- EPS
- $1.11 · 40.51%
- Op Income
- $13.32M
- FCF YoY
- -25.45%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -20.47
- Avg Volume
- 3.17K
Get TickerSpark's AI analysis on TBET
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TBET Coverage
We haven't published any research on TBET yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TBET Report →